Safer thrombolysis for acute ischemic stroke: Is early recanalization the key?

Neurology

Volumn 71, Issue 17, 2008, Pages 1300-1301

  Tanne, David ^a,b   Levine, Steven R ^c  

^a SHEBA MEDICAL CENTER   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

^c MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALTEPLASE; TENECTEPLASE; TISSUE PLASMINOGEN ACTIVATOR;

ACUTE DISEASE; BLOOD BRAIN BARRIER; BRAIN EDEMA; BRAIN HEMORRHAGE; BRAIN TISSUE; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; DETERIORATION; DISABILITY; DISEASE COURSE; DOPPLER ECHOGRAPHY; DRUG EFFECT; EARLY INTERVENTION; EDITORIAL; EMBOLECTOMY; FIBRINOLYTIC THERAPY; HUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OCCLUSIVE CEREBROVASCULAR DISEASE; PRIORITY JOURNAL; RECANALIZATION; REPERFUSION; RISK BENEFIT ANALYSIS; TREATMENT DURATION; TREATMENT OUTCOME; BRAIN ISCHEMIA; METHODOLOGY; NOTE; PATHOLOGY; STROKE;

BRAIN ISCHEMIA; HUMANS; REPERFUSION; STROKE; THROMBOLYTIC THERAPY; TISSUE PLASMINOGEN ACTIVATOR;

EID: 55449088398     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/01.wnl.0000327700.34223.8e     Document Type: Editorial

References (10)

1. National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med 1995;333:1581- 1588.
2. Tanne D, Kasner SE, Demchuk AM, et al., the Multi-center rt-PA Stroke Survey Group. Markers of increased risk of intracerebral hemorrhage after intravenous recom-binant tissue plasminogen activator therapy for acute isch-emic stroke in clinical practice: the Multicenter rt-PA Acute Stroke Survey. Circulation 2002;105:1679-1685.
3. Saver JL. Number needed to treat estimates incorporating effects over the entire range of clinical outcomes: novel derivation method and application to thrombolytic therapy for acute stroke. Arch Neurol 2004;61:1066-1070.
4. Delgado-Mederos R, Rovira A, Alvarez-Sabin J, et al. Speed of tPA-induced clot lysis predicts DWI lesion evolution in acute stroke. Stroke 2007;38:955-960.
5. Hacke W, Donnan G, Fieschi C, et al. Association of out-come with early stroke treatment: pooled analysis of Atlantis, ECASS, and NINDS rt-PA stroke trials. Lancet 2004; 363:768-774.
6. Saqqur M, Tsivgoulis G, Molina CA, et al., for the CLOTBUST Investigators. Symptomatic intracerebral hemorrhage and recanalization after IV rt-PA: a multi-center study. Neurology 2008;71:1304-1312.
7. Kidwell CS, Latour L, Saver JL, et al. Thrombolytic toxicity: blood brain barrier disruption in human ischemic stroke. Cerebrovasc Dis 2008;25:338-343.
8. Cheng T, Petraglia AL, Li Z, et al. Activated protein C inhibits tissue plasminogen activator-induced brain hemorrhage. Nat Med 2006;12:1278-1285.
9. Wunderlich MT, Goertler M, Postert T, et al., for the Duplex Sonography in Acute Stroke (DIAS) Study Group and the Competence Network Stroke. Recanalization after intravenous thrombolysis: does a recanalization time window exist? Neurology 2007;68:1364-1368.
10. Molina CA, Alvarez-Sabin J, Montaner J, et al. Thrombolysis-related hemorrhagic infarction: a marker of early reperfusion, reduced infarct size, and improved out-come in patients with proximal middle cerebral artery occlusion. Stroke 2002;33:1551-1556.